CVM Cel Sci Corp

Price (delayed)

$1.31

Market cap

$70.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.63

Enterprise value

$75.94M

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients ...

Highlights
The company's EPS rose by 23% YoY and by 9% QoQ
CVM's net income is up by 15% year-on-year and by 3.5% since the previous quarter
Cel Sci's quick ratio has decreased by 36% YoY but it has increased by 30% from the previous quarter
The equity has decreased by 29% YoY but it has increased by 13% from the previous quarter

Key stats

What are the main financial stats of CVM
Market
Shares outstanding
54.16M
Market cap
$70.95M
Enterprise value
$75.94M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.59
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$29.21M
EBITDA
-$25.22M
Free cash flow
-$20.37M
Per share
EPS
-$0.63
Free cash flow per share
-$0.39
Book value per share
$0.29
Revenue per share
$0
TBVPS
$0.57
Balance sheet
Total assets
$30.05M
Total liabilities
$15.74M
Debt
$12.63M
Equity
$14.3M
Working capital
$3.42M
Liquidity
Debt to equity
0.88
Current ratio
1.67
Quick ratio
1.5
Net debt/EBITDA
-0.2
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-98.5%
Return on equity
-218%
Return on invested capital
-92.6%
Return on capital employed
-117%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CVM stock price

How has the Cel Sci stock price performed over time
Intraday
2.34%
1 week
6.5%
1 month
0.77%
1 year
-48.83%
YTD
-51.84%
QTD
12.93%

Financial performance

How have Cel Sci's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.17M
Net income
-$29.95M
Gross margin
N/A
Net margin
N/A
CVM's net income is up by 15% year-on-year and by 3.5% since the previous quarter
Cel Sci's operating income has increased by 13% YoY and by 3.7% from the previous quarter

Growth

What is Cel Sci's growth rate over time

Valuation

What is Cel Sci stock price valuation
P/E
N/A
P/B
4.59
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 23% YoY and by 9% QoQ
The stock's price to book (P/B) is 70% less than its 5-year quarterly average of 15.1 and 39% less than its last 4 quarters average of 7.3
The equity has decreased by 29% YoY but it has increased by 13% from the previous quarter

Efficiency

How efficient is Cel Sci business performance
CVM's return on equity has dropped by 81% year-on-year and by 7% since the previous quarter
The return on assets has declined by 32% year-on-year and by 2.9% since the previous quarter

Dividends

What is CVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CVM.

Financial health

How did Cel Sci financials performed over time
The total assets is 91% more than the total liabilities
Cel Sci's quick ratio has decreased by 36% YoY but it has increased by 30% from the previous quarter
Cel Sci's current ratio has increased by 33% from the previous quarter but it has decreased by 30% YoY
CVM's debt is 12% smaller than its equity
The equity has decreased by 29% YoY but it has increased by 13% from the previous quarter
The company's debt to equity rose by 22% YoY but it fell by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.